



# BEDFORDSHIRE, LUTON AND MILTON KEYNES AREA PRESCRIBING COMMITTEE (APC)

# **Icosapent Ethyl Prescribing Guidance**

Ratified by BLMK APC Sept 2022

The following organisations contribute to and participate in the BLMK APC – Bedfordshire, Luton and Milton Keynes Integrated Care Board; Bedfordshire Hospitals NHS Foundation Trust; Cambridgeshire Community Services NHS Trust; Central and North West London NHS Foundation Trust; East London NHS Foundation Trust; Milton Keynes University Hospital NHS






## **Icosapent Ethyl 998mg Capsules Prescribing Guidance**

The NICE Technology Appraisal TA805 recommends Icosapent ethyl as an option for reducing the risk of cardiovascular events in adults with a raised fasting triglyceride of 1.7 mmol/litre or above and are taking statins, have established cardiovascular disease and a low-density lipoprotein cholesterol (LDL-C) levels above 1.04 mmol/litre and below or equal to 2.60 mmol/litre.

Full prescribing information can be found in the products Summary of Product Characteristics.

### **Eligibility Criteria**

- Established cardiovascular disease (angina, previous MI, revascularisation, stroke or TIA or symptomatic peripheral arterial
- On maximally tolerated statin for at least 3 months



#### Prescribe:

- Icosapent ethyl 998mg capsules:
- **Take:** 4 capsules; taken as two x 998 mg capsules twice daily
- To ensure the full intended dose is received, patients should be advised to swallow the capsules whole and not to break, crush, dissolve, or chew them.
- No dosage adjustment required for renal or hepatic impairment

<sup>\*</sup> https://www.england.nhs.uk/aac/wp-content/uploads/sites/50/2020/04/Summary-of-national-guidance-for-lipidmanagement-for-primary-and-secondary-prevention-of-cardiovascular-disea.pdf